Piperaquine Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers of Papua New Guinea after Administration of Three-Monthly Doses of Dihydroartemisinin

Piperaquine Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers of Papua New Guinea after Administration of Three-Monthly Doses of Dihydroartemisinin–Piperaquine

Published:2022-08-16 Issue:8 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Millat-Martínez Pere¹^ORCID,Salman Sam²³⁴^ORCID,Moore Brioni R.²⁵⁶,Baro Bàrbara¹,Page-Sharp Madhu⁵,Batty Kevin T.⁵⁶^ORCID,Robinson Leanne J.⁷⁸⁹¹⁰,Pomat William⁷,Karunajeewa Harin⁹¹¹,Laman Moses⁷,Manning Laurens²⁴¹²,Mitjà Oriol¹³¹⁴¹⁵¹⁶^ORCID,Bassat Quique¹¹⁷¹⁸¹⁹²⁰^ORCID

Affiliation:

1. ISGlobal, Hospital Clínic—Universitat de Barcelona, Barcelona, Spain

2. Medical School, The University of Western Australia, Crawley, Perth, Western Australia, Australia

3. Clinical Pharmacology and Toxicology, PathWest, Nedlands, Western Australia, Australia

4. Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia

5. Curtin Medical School, Curtin University, Bentley, Perth, Western Australia, Australia

6. Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Western Australia, Australia

7. Vector-borne Diseases Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea

8. Burnet Institute, Melbourne, Victoria, Australia

9. The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia

10. Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia

11. Department of Medicine-Western Health, The University of Melbourne, Melbourne, Victoria, Australia

12. Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

13. Fight AIDS and Infectious Diseases Foundation, Badalona, Spain

14. Infectious Disease Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

15. Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain

16. Lihir Medical Centre, International SOS, Lihir Island, Papua New Guinea

17. ICREA, Pg. Lluís Companys 23, Barcelona, Spain

18. Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Barcelona, Spain

19. Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique

20. Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

Abstract

Mass drug administration (MDA) with monthly dihydroartemisinin-piperaquine (DHA-PQP) appears useful in malaria control and elimination strategies. Determining the relationship between consecutive piperaquine phosphate (PQP) exposure and its impact on QT interval prolongation is a key safety consideration for MDA campaigns.

Funder

Medicines for Malaria Venture

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00185-22

Reference34 articles.

1. World Health Organization. 2015. Guidelines for the treatment of malaria, 3rd ed. World Health Organization, Geneva, Switzerland.

2. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria;Zani B;Cochrane Database Syst Rev,2014

3. World Health Organization. 2015. Recommendations on the role of mass drug administration, mass screening and treatment, and focal screening and treatment for malaria. World Health Organization, Geneva, Switzerland.

4. Review of Mass Drug Administration for Malaria and Its Operational Challenges

5. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial